sodium zirconium cyclosilicate
Source Category: Curation Efforts. The FDA approval is supported by … 1. LOKELMA ® (sodium zirconium cyclosilicate) is not indicated to reduce the risk of death. Lokelma should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action. 2. UZSi 9. None. It has a mean particle size of 20 µm and includes no more than 3% of particles with a diameter below 3 µm. Commercial arrangement. Feces . Help. If you are in the US and would like additional information regarding AstraZeneca drugs, please contact the Information Center at AstraZeneca at 800-236-9933 800-236-9933. Sodium zirconium cyclosilicate (SZC) is a new potassium binder recently approved for the treatment of chronic hyperkalemia. 質量 : 559.8698. LOKELMA contains 400 mg of sodium in each 5 g dose. ZS 9. 25 In acute symptomatic hyperkalemia, extracellular potassium can be lowered by shifting it into the intracellular compartment. Generic Name: sodium zirconium cyclosilicate Brand Name: Lokelma Manufacturer: AstraZeneca Canada Inc. It is ingested as an oral powder dispersed in liquid, is insoluble, and is not absorbed by the gut. 米国の商品 : LOKELMA (AstraZeneca Pharmaceuticals LP) 組成式 : ZrH4O6. Sodium zirconium cyclosilicate (ZS‐9) is a new oral agent used in the management of hyperkalaemia. Drug: Sodium Zirconium Cyclosilicate(ZS) Suspension administered orally for a treatment period of 24h. Single dose contains 2 sachets of ZS 5g. Watch for signs of swelling in your body especially if you limit sodium in your diet or are likely to have fluid retention in your body due to heart or kidney problems. 1,11 It does not expand when mixed with water, unlike sodium polystyrene sulfonate, which expands to 80% to 100% of its original volume. sodium zirconium cyclosilicate. Researchers reported results of the phase 3b DIALIZE study that examined sodium zirconium cyclosilicate (SZC) in the management of hyperkalemia in patients with end-stage renal disease on maintenance hemodialysis. Serum K + ≥5.0 mEq/L was associated with an increased risk of all-cause mortality in patients with HF, diabetes, CKD, all 3, or none of these comorbidities. LOKELMA is a odorless, insoluble white to grey powder for oral suspension. Revision History. Epub 2020 Sep 7 doi: 10.1080/14656566.2020.1810234. Help. Help. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, lowering serum potassium levels. If any powder remains in the cup, add more water, then stir and drink. Lokelma is a highly-selective, oral potassium-removing agent. (Monday to Friday, 8 AM to 8 PM ET, excluding holidays. Excretion. Dosage and Administration. Etiology. Contents. Evidence-based recommendations on sodium zirconium cyclosilicate (Lokelma) for treating hyperkalaemia in adults. New Window. Palmer BF. 4.1 Pregnancy Rating; 4.2 Lactation risk; 4.3 Renal Dosing; 4.4 Hepatic Dosing; 5 Contraindications; 6 Adverse Reactions. If you are not on dialysis, your doctor may also tell you to increase the dose of your diuretic. This action removes potassium from the body overall, thus helping to lower the potassium levels in the blood. MeSH. Stir and drink immediately. Related Compounds: PubChem CID. Lokelma (Sodium zirconium cyclosilicate): AstraZeneca . Status: Live. 3 Chemical and Physical Properties. ZS‐9, a selective potassium binder, is the first in its drug class. Onset of Action. The real question is how effective it may be. Mechanism of action. Sodium zirconium cyclosilicate (Lokelma™) [hereafter referred to as SZC] is a non-absorbed, non-polymer zirconium silicate compound that preferentially exchanges hydrogen and sodium for potassium and ammonium ions in the gastrointestinal tract (GIT), thereby increasing faecal potassium excretion and lowering serum potassium levels. Mayo Clin Proc. There is a simple discount patient access scheme for sodium zirconium cyclosilicate. ZS-9 compound. Potassium binders for hyperkalemia in chronic kidney disease–diet, renin-angiotensin-aldosterone system inhibitor therapy, and hemodialysis. 1 4 Administer sodium zirconium cyclosilicate ≥2 hours before or ≥2 hours after other oral drugs unless it is determined that the other drug does not exhibit pH-dependent solubility. 3H4SiO4. Sodium zirconium cyclosilicate. Sodium zirconium cyclosilicate (USAN) Cite. Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review. Sodium Zirconium Cyclosilicate (SZC) is a potassium-exchange resin similar in concept to sodium polystyrene sulfonate (Kayexalate). Your doctor may tell you to reduce the sodium in your diet. Sodium zirconium cyclosilicate has been shown to be effective and safe in adults for the treatment of hyperkalaemia, and therefore it is expected to be beneficial in children. Takkar C, Nassar T, Qunibi W Expert Opin Pharmacother 2021 Jan;22(1):19-28. 2017;12:11-24. Sodium zirconium cyclosilicate is a nonabsorbed, potassium-binding, inorganic cation exchange crystalline compound formulated as an insoluble, odorless, and tasteless white powder. Contact Market.AccessUK@astrazeneca.com for details. As a non-absorbed, non-polymer compound, SZC lowers serum potassium levels by binding potassium in the gastrointestinal (GI) tract and promoting faecal potassium excretion. Sodium zirconium silicate (Na2ZrSi3O9) UZSi-9. 1 hour. Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: An … Not systemically absorbed. Toggle navigation. An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia. 2 It is administered orally and is odorless, tasteless, and stable at room temperature. Cross-sections of ZS-9 pores with three different ions (K⁺ = potassium, Na⁺ = sodium, Ca²⁺ =... History. Sodium zirconium cyclosilicate causes transient increases in gastric pH and can affect solubility (and consequent bioavailability) of certain pH-dependent drugs. When used chronically, maintenance of normal serum potassium has been demonstrated for up to 1 month. 3.1 Computed Properties. 2.4.2 Depositor-Supplied Synonyms. Sodium zirconium cyclosilicate (ZS-9) is a highly selective cation exchanger that entraps potassium in the intestinal tract in exchange for sodium and hydrogen (Fig. 1 This is a potentially serious condition caused by raised potassium levels in the blood and is frequently associated with chronic kidney disease, heart failure and diabetes. 2Na. The FDA has approved sodium zirconium cyclosilicate -- a medication that rapidly restores normal potassium levels -- for adults with hyperkalemia. It also explained that sodium zirconium cyclosilicate would be prescribed in secondary care, that is, in hospitals. Is this guidance up to date? Metabolism. Download. The primary end point was the proportion of patients during the 4-week stable dose evaluation period who … Each 5 g of sodium zirconium cyclosilicate contains 400 mg of sodium. 2.1 Hyperkalemia; 3 Pediatric Dosing; 4 Special Populations. Medical. PubChem SID: 254741688: Structure: Source: KEGG. New Window. Property Name Property Value Reference ; Molecular Weight: 371.5 g/mol: Computed by … Areas covered: Sodium zirconium cyclosilicate (ZS-9), a novel, non-absorbed, potassium-selective cation exchanger, has demonstrated activity in acutely lowering and maintaining normal potassium levels. Efficacy data for short-term improvement in potassium. Sodium zirconium cyclosilicate is a potassium binder that preferentially exchanges potassium for hydrogen and sodium. 1 Administration [1] 2 Adult Dosing. Research and Development. 2H2O. Sodium zirconium cyclosilicate is a non-absorbed zirconium silicate that preferentially exchanges potassium for hydrogen and sodium. CID 92042806 (Lokelma (TN)) Component CID. ZS-9 compound. . The FDA approval is supported by data from three double-blind, placebo-controlled trials and two open-label trials, which showed that for patients receiving Lokelma, the onset of action was at 1.0 h and the median time to achieving normal potassium levels in … This study will evaluate the efficacy, safety and tolerability of sodium zirconium cyclosilicate for the treatment of hyperkalaemia in children <18 years of age. It’s not particularly new, as the original studies were performed around 2015. Sodium zirconium cyclosilicate (USAN); Sodium zirconium cyclosilicate hydrate (JAN) 商品名 : ロケルマ (アストラゼネカ) 商品一覧 . Your doctor may tell you to reduce the sodium in your diet. Lokelma (sodium zirconium cyclosilicate) is a prescription drug that treats hyperkalemia in adults. Use: Labeled Indications. Version: 4. Repeat as … Lokelma (sodium zirconium cyclosilicate) is a potassium binder indicated for the treatment of hyperkalemia in adults. PMID: 32892634. More recently sodium zirconium cyclosilicate was introduced, which is a highly sensitive potassium binder that traps potassium in exchange for sodium or hydrogen ions. Pharmacology. LOKELMA contains 400 mg of sodium in each 5 g dose. It explained that sodium zirconium cyclosilicate would complement rather than replace a low-potassium diet and may allow such a diet to be less strict (see section 3.5). 11. Sodium zirconium cyclosilicate is used to treat high blood potassium. Absorption. Sodium zirconium cyclosilicate (SZC) [Lokelma™] is a useful oral option for the treatment of hyperkalaemia in adults. Sodium zirconium cyclosilicate is an insoluble, non-absorbed, non-polymer inorganic material designed to bind potassium ions with proven selectivity to treat hyperkalaemia. Watch for signs of swelling in your body especially if you limit sodium in your diet or are likely to have fluid retention in your body due to heart or kidney problems. Marketed ProductsLokelma (Sodium zirconium cyclosilicate): AstraZenecaLokelma is a highly-selective, oral potassium-removing agent. For maintenance treatment, … Next review: 2022. Sodium zirconium cyclosilicate Medical use. New Window. Sodium zirconium cyclosilicate; Recent clinical studies. Patients were randomized to receive SZC (n=97) or placebo (n=99). Find prescribing information for LOKELMA™ (sodium zirconium cyclosilicate) from AstraZeneca. 3. Core Evid. Learn about side effects, dosage, and more. When taken by mouth, Lokelma attaches to potassium from food and body fluids in the gut, forming a compound that is then eliminated in the stools. Therapeutic Area: Hyperkalemia, adults Indications: Hyperkalemia, adults Manufacturer Requested Reimbursement Criteria 1: Corrective treatment of hyperkalemia in adult patients (10 g administered three times per day, for 48 hours but up to 72 hours as needed), in line with the … CID 962 (Water) CID 14942 (Orthosilicic acid) CID 23995 (Zirconium) CID 5360545 (Sodium … 10. 6.1 Serious; 6.2 Common; 7 Pharmacology; 8 Mechanism of Action; 9 Comments; 10 See Also; 11 References; Administration. Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent. 2020;95(2):339-354. To mix the powder, follow these steps: Empty the packet (s) of sodium zirconium cyclosilicate powder into a cup of 3 tablespoons (45 mL) or more of water. Recommended starting dose is 10 g administered three times a day for up to 48 hours. Accumulating evidence over the last five years supports the drug’s safety. External ID: D10727. PubChem. 分子量 : 561.6068. 17141-74-1. 10g administered up to three times over 10h (at 0, 4 and 10h). The active substance in Lokelma, sodium zirconium cyclosilicate, is a potassium binder.